Amylin data doesn't impress Wall Street

It's good data, but is it good enough? Amylin Pharmaceuticals announced that its once-a-week version of the diabetes drug Byetta works better than the twice-a-day version now on the market. It was welcome news for Amylin and its partners Eli Lilly and Alkermes. And potentially for diabetes patients, because keeping the drug at a steady level in the body could be better at preventing complications from blood sugar fluctuations. (Caveat: The FDA warned last month that some Byetta patients developed acute pancreatitis.)

But some stock analysts were disappointed that the difference in efficacy of the two dosing schemes wasn't more dramatic. And others bemoaned the fact that Amylin doesn't intend to ask the FDA to approve the new-and-improved Byetta until 2009. Amylin stock fell 3.8 percent to $46.52.

- see the release from Amylin
- read the San Diego Union-Tribune report
- check out more on the financial angles from the Motley Fool

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.